Stryker Mako Orthopedic Surgical Robotics

Mako Platform Reality

Stryker acquired Mako Surgical in 2013 and has since built the orthopedic robotics platform into the procedural anchor of its joint reconstruction business. Mako Total Knee is the volume driver, with Mako Total Hip operating across both anterior and posterior approaches. Mako Partial Knee preceded both as the original indication, and Mako Total Shoulder rounded out the upper-extremity coverage following recent FDA clearance. Across these indications, Stryker reports cumulative procedure counts in the high seven figures and an installed base whose competitive moat is reinforced by implant pull-through: each Mako system meaningfully biases hospital purchasing toward Stryker's Triathlon, Insignia, and Tornier implant families.

Operationally, Mako today is a haptically constrained cutting guide. The surgeon performs a CT-based pre-operative plan, registers the patient anatomy intra-operatively, and executes bone resection through a robotic arm that physically prevents excursion outside the planned envelope. The robot does not make autonomous cuts. It does not advance the burr or saw on its own initiative. It enforces a boundary, and the surgeon supplies the motive force. This is the regulatory and clinical equilibrium that the platform has occupied for a decade.

Path Toward Autonomous Phases

The economic and clinical pressure on Stryker is to extend autonomy further into the procedure — autonomous registration verification, autonomous burr advancement within haptic envelopes, autonomous soft-tissue balancing assessment, and ultimately autonomous execution of well-circumscribed sub-phases such as tibial plateau preparation. Each step toward autonomy crosses a regulatory threshold that the FDA has begun to formalize through the Predetermined Change Control Plan (PCCP) framework, which contemplates iterative software updates to AI-enabled medical devices under a pre-cleared modification protocol.

The structural problem is that PCCP, as currently practiced, governs model updates rather than authority delegation. It does not natively express the question Mako needs to answer at every sub-phase boundary: under what conditions may this actuator advance from advisory to assistive to autonomous, and under what conditions must it retreat? Stryker's regulatory submissions, surgeon training curricula, and post-market surveillance all encode parts of this answer, but the encoding is implicit, distributed across documents, and not machine-checkable in the operating room at the moment a sub-phase begins.

Governed actuation makes the encoding explicit. It defines graduated actuation modes — observe, advise, assist, execute — and binds each mode to admissibility predicates that combine surgeon credentialing, intra-operative registration confidence, soft-tissue state, and the reversibility classification of the pending action. Bone resection is irreversible. Pin placement is partially reversible. Trial implant insertion is reversible. The actuation mode admissible at any moment is the floor across these dimensions, and the substrate computes that floor continuously rather than at submission time.

Architectural Fit for Mako Sub-Phases

A Mako Total Knee procedure decomposes into roughly a dozen sub-phases: exposure, array placement, registration, gap balancing, femoral resection, tibial resection, trial reduction, final implantation, and closure, with intermediate verification steps. Each sub-phase has a distinct reversibility profile and a distinct admissibility envelope. Governed actuation lets Stryker bind each sub-phase to a stage gate whose entry condition is composite: the surgeon must hold the credential, the registration must hold to within a stated tolerance, the prior sub-phase must have closed cleanly, and the pending action must be classified at or below the reversibility ceiling for the currently admissible mode.

Reversibility-aware execution then governs what happens inside the gate. For an irreversible action — the actual cut — the substrate requires that authority remain with the surgeon and that the robot operate in assist mode only, regardless of how confident the planning model is. For a reversible action — a trial reduction — the substrate may admit execute mode under tighter telemetry, because a wrong outcome is recoverable by retraction. The gradation is not a marketing choice; it is a structural property of the action itself, and governed actuation makes that property a first-class operand.

The composition extends to multi-vendor scenarios that Stryker increasingly faces. Hospitals using Mako alongside navigation systems from competing vendors, intra-operative imaging from third parties, and implant components from Stryker's own catalog need a substrate that can admit cross-vendor observations without flattening the authority chain. Composite admissibility — where each contributing system supplies credentialed observations and the gate evaluates the composite — gives Stryker a way to integrate without surrendering the actuation envelope.

Stryker Position

Stryker's competitive position rests on the installed base and the implant pull-through, but the medium-term threat is not another robot — it is a regulatory environment that begins to demand explicit authority models for autonomous-phase operation, and a Stryker that has only the implicit version. Zimmer Biomet's ROSA, Smith and Nephew's CORI, and Johnson and Johnson's VELYS are each pursuing autonomy increments, and the first vendor to present the FDA with a stage-gated actuation model that the agency can evaluate as a structural artifact rather than a stack of submissions will set the regulatory cadence for the category.

Adopting governed actuation as the platform substrate gives Stryker FDA-aligned architectural ground ahead of pure-platform-replacement competitive pressure. It converts the implicit authority model that Mako already operates under into an explicit, auditable, machine-checkable artifact, which is the form the next wave of regulation will require. It positions Stryker's 70% market share not as a defensive asset but as the deployment substrate against which graduated autonomy is first proven, and it lets the implant pull-through compound into a software-and-authority moat that competing vendors cannot replicate by shipping a comparable arm.

The decision Stryker faces is not whether to add autonomy — clinical and economic pressure makes that direction certain — but whether to add it as a series of bespoke clearances or as an architectural element. Governed actuation is the architectural element.